In an interview with pharmaphorum, Jennifer Lee, director of health economics, market access and reimbursement and advocacy at Janssen Cilag, said the company welcomes the evolution of the CDF ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

The European Commission (EC) has approved the extension of indication for Janssen-Cilag International’s Darzalex (daratumumab) subcutaneous (SC) formulation to be used in the frontline setting ...

Eva Thalmann obtained a PhD in Biochemistry from the University of Vienna and joined Janssen-Cilag in 1990. She had various positions in Medical Affairs and Strategic Marketing for Janssen and ...

If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen-Cilag ...

One million Australians could be forced to fork out more for medicines used to treat ADHD as widespread shortages could last ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen-Cilag ...